Synthetic recombinant DNA delivery for cancer therapeutics
Felgner, P.L.; Zaugg, R.H.; Norman, J.A.
Cancer Gene Therapy 2(1): 61-65
1995
ISSN/ISBN: 0929-1903 PMID: 7621256 Document Number: 449765
Document emailed within 1 workday
Related Documents
Ranasinghe, L. 1983: Recombinant technology in medical research and therapeutics Ceylon Medical Journal 28(2): 57-61Irvine, K.R.; McCabe, B.J.; Rosenberg, S.A.; Restifo, N.P. 1995: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL Journal of Immunology 154(9): 4651-4657
Holland, J.F.; Ohnuma, T. 1981: Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators Cancer Treatment Reports 65(Suppl 4): 123-130
McMannis, J.D.; Fisher, R.I.; Creekmore, S.P.; Braun, D.P.; Harris, J.E.; Ellis, T.M. 1988: In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2 Journal of Immunology 140(4): 1335-1340
Pala, P.; Corradin, G.; Strachan, T.; Sodoyer, R.; Jordan, B.R.; Cerottini, J.C.; Maryanski, J.L. 1988: Mapping of HLA epitopes recognized by H-2-restricted cytotoxic T lymphocytes specific for HLA using recombinant genes and synthetic peptides Journal of Immunology 140(3): 871-877
Jurincic-Winkler, C.; Horlbeck, R.; Klippel, K.F. 1993: Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer Wiener Klinische Wochenschrift 105(10): 271-276
Abbruzzese, J.L.; Levin, B.; Ajani, J.A.; Faintuch, J.S.; Saks, S.; Patt, Y.Z.; Edwards, C.; Ende, K.; Gutterman, J.U. 1989: Phase i trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Research 49(14): 4057-4061
DeVita, V.T. 1983: Advances in cancer therapeutics: chemotherapy Progress in Clinical and Biological Research 132a: 47-69
Mahmud, S.M.; Mek, K.J.; Idris, A. 2016: Intracellular Delivery of Synthetic dsRNA to Leukemic Cells Induces Apoptotic and Necrotic Cell Death Folia Biologica 62(2): 90-94
Wehrlin, N. 1983: Therapeutics: hormone therapy for breast cancer Revue de l'Infirmiere 33(11): 35-38
Masucci, G.; Mellstedt, H. 1990: Biologic therapeutics as the fourth modality in cancer treatment Leukemia 4(2): 81-82
Brissette, R.; Prendergast, J.K.A.; Goldstein, N.I. 2006: Identification of cancer targets and therapeutics using phage display Current Opinion in Drug Discovery and Development 9(3): 363-369
Shen, Y. 2008: Advances in the development of siRNA-based therapeutics for cancer Idrugs: the Investigational Drugs Journal 11(8): 572-578
Wang, D.Y.; Sosman, J.A.; Johnson, D.B. 2015: Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics Oncology 29(12): 1005-1006
Gnatenko, D.; Arnold, T.E.; Zolotukhin, S.; Nuovo, G.J.; Muzyczka, N.; Bahou, W.F. 1997: Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research 45(2): 87-98
Shiota, M.; Yokomizo, A.; Naito, S. 2014: The development of therapeutics targeting oxidative stress in prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2131-2135
Zhang, T.-Y.; Hu, Y.-L.; Liang, W.-Q.; Gao, J.-Q. 2013: Research progress of gene recombinant mesenchymal stem cells as tumor targeting delivery vehicles Yao Xue Xue Bao 48(8): 1209-1220
Fujita, T.; Nishikawa, M.; Tamaki, C.; Takakura, Y.; Hashida, M.; Sezaki, H. 1992: Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives Journal of Pharmacology and Experimental Therapeutics 263(3): 971-978
Garvey, R. 2006: AACR-NCI-EORTC--17th Symposium: Molecular Targets and Cancer Therapeutics IDrugs: the investigational drugs journal 9(2): 90-92
Ivy, S.Percy.; Ivy, S.Percy. 2015: The National Cancer Institute's Experimental Therapeutics Clinical Trials Network Clinical Advances in Hematology and Oncology: H&o 13(3): 144-146